ABSTRACT
INTRODUCTION
Glutathione S-transferases (GSTs) are responsible for the cellular metabolism as well as detoxification of several xenobiotics and carcinogenic compounds primarily in the liver and, to a much lesser extent, in the extrahepatic organs. Glutathione conjugates formed in the liver can either be excreted intact in bile, or they can be converted to mercapturic acids in the kidney and excreted in the urine (1) . The loss of GST protection can increase the susceptibility of preneoplastic hepatocytes to chemical-induced genotoxicity during chemical carcinogenesis. Therefore, GST induction is not only for cell detoxification and survival but also cancer prevention.
The activation of the antioxidant response element (ARE) by reactive oxygen species from prooxidants contributes to the regulation of Phase II enzymes, including the GSTs (2, 3) . The signals activated by oxidative stress stimulate the transduction of NF-E2-related factor (Nrf) activity and ARE activation (4, 5) . The protein binding to the ARE consensus sequence involves the Nrf proteins, as well as Maf family members (6, 7) . Oxidative stress induces GSTA2 via ARE activation, which involves the Nrf proteins (8, 9) . Transcription factors of the CCAAT/enhancer binding protein (C/EBP) family play roles in cell differentiation and exert their function by regulating the expression of tissue-specific genes, as well as cell proliferation (10, 11) . In response to growth stimuli, the members of the C/EBP family involved in the transcription of the tissue-specific genes include C/EBP␤ and C/EBP␦ (12) . C/EBP constitutes an essential distinct pathway for GST induction. Previous studies have shown that C/EBP␤ activation and its binding to the C/EBP-response element plays a crucial role in the induction of the GSTA2 gene (13, 14) .
The peroxisome proliferator-activated receptors (PPARs) are wellcharacterized transcription factors that are members of the nuclear hormone receptor superfamily (15) . There are three PPARs subtypes, including PPAR␣, PPAR␤, and PPAR␥, which have distinct distribution patterns. PPAR␣ is mainly present in the liver, heart, and kidney, whereas PPAR␤ is expressed ubiquitously (15) . PPAR␥ is predominantly expressed in the adipose tissue and, to a lesser extent, in the liver (15) . PPAR␥ activators up-regulate the expression of the genes involved in adipocyte differentiation (16) . Although the basal expression of the PPAR␥ in the liver is relatively low, hepatic PPAR␥ is pronouncedly up-regulated by PPAR␥ activators and under certain pathophysiological conditions (e.g., obesity) for the activation of several PPAR␥-responsive genes (17, 18) . PPAR␥ is also an important target for the development of new drugs aimed at preventing and treating cancer. A deficiency in PPAR␥ expression can be a significant risk factor for carcinogenesis (19) . Ligands for PPAR␥ suppress carcinogenesis in experimental models and induce the differentiation of human tumorigenic cells (20 -23) . The activated PPAR␥ forms a heterodimer with retinoid X receptor (RXR)␣ and binds to specific PPAR response elements in the promoter region of their target genes (24) . Therefore, PPAR␥ agonists affect cell survival, growth, and differentiation by binding to the peroxisomal proliferator-response element (PPRE).
Hepatic stellate cells in the liver contain 40 -70% of the body stores of retinoids. Retinoic acids, which are natural metabolites of circulating vitamin A, are essential for maintaining the normal pathway of epithelial tissues differentiation (25) . Natural and synthetic retinoids are also effective in preventing a variety of cancers in animals and in reversing preneoplastic lesions in humans (26 -29) . A large-scale study of the cancer chemopreventive role of retinoic acids in human has shown that retinoids exhibit a high degree of specificity in cancer chemoprevention (30) . The major retinoids responsible for the transcriptional regulation of many processes in the development and differentiation are all-trans and 9-cis-retinoic acids (RAs), which affect the important biological processes via their interaction with the nuclear receptors (25) . In particular, RA was identified as an activating ligand that is relatively selective for RXR␣, which must heterodimerize with a permissive partner (24, 31, 32) . RXR␣ is essential for the high-affinity DNA binding of PPAR and serves as an auxiliary DNA-binding factor.
From these observations, it is possible that PPAR␥ and RXR␣ agonists activate the expression of the liver-specific genes at the transcriptional level. The liver-specific target genes may include GSTs because there is an extremely high (i.e., ϳ10 mM) concentration of glutathione in the liver. The conjugation of xenobiotics with glutathione, which are catalyzed by all classes of GSTs, is fundamentally different from their conjugation with other amino acids, because the substrates of glutathione conjugation include an enormous range of electrophilic xenobiotics or xenobiotics, which are biotransformed to electrophiles (33) . The GSTA2 gene is a representative member of the class ␣ GSTs that contains a xenobiotic-response element, putative phenobarbital-responsive element, glucocorticoid-responsive element, and an ARE. However, no functionally active PPRE or PPRE-responsive enhancer module (PPREM) has yet been identified in the GSTA2 gene. In the present study, we initially found the putative multiple PPREs in the promoter region of the GSTA2 gene. We determined whether the PPAR␥ and RXR activators induce GSTA2 via activating PPAR␥ Ϫ RXR heterodimer binding to the putative PPREs in H4IIE hepatocytes and, if so, whether the putative PPREs function as a module where there needs to be multiple nuclear binding sites in close proximity. We used 15-deoxy-␦ (12, 14)-prostaglandin J 2 (PGJ 2 ) and thiazolidinedione PPAR␥ ligands as the PPAR␥ agonists. It was found that the combined treatment of the PPAR␥ agonist and RA both activated and induced Nrf2 and C/EBP␤, which are the essential transcription factors for GSTA2 expression. More importantly, the PPAR-binding site cluster in the GSTA2 gene was identified as a functionally active PPREM.
MATERIALS AND METHODS

Materials. [␣-
32 P]dCTP (3000 mCi/mmol) and [␥-32 P]ATP (3000 mCi/ mmol) were purchased from New England Nuclear (Arlington Heights, IL). The random prime-labeling kit was supplied by Promega (Madison, WI). PGJ 2 and troglitazone were purchased from Biomol Research Labs (St. Louis, MO). Pioglitazone and rosiglitazone were kindly supplied from Dong-A Pharmaceutical Co. (Shingal, Korea). RA, DTT, and 3-[N-morpholino]propanesulfonic acid were provided from Sigma Chemical (St. Louis, MO). Anti-PPAR␥ antibody and anti-RXR␣ antibody were obtained from Santa Cruz Biotechnology (Santa Cruz, CA). The plasmid pGTB-1.65 construct containing the GSTA2-promoter region (Ϫ1651 to ϩ66 bp from the transcription start site) was kindly provided by Dr. C. B. Pickett (Schering-Plough Corp. Inst., Kenilworth, NJ), and the C/EBP dominant-negative expression (AC/EBP) plasmid was a gift from Dr. C. Vinson (NIH, Besthesda, MD; Ref. 34) . AC/EBP prevents the "normal" C/EBP from binding to DNA because C/EBP acts as a dimer. The expression plasmid of mouse PPAR␥1 (i.e., pCMX-mPPAR␥1) was kindly supplied from Dr. C. K. Glass (University of California, San Diego, CA). The human RXR␣ expression plasmid (PECE-RXR␣) was provided by Dr. M. O. Lee (Sejong University, Seoul, Korea).
Construction of Plasmids. The pGL-1651 reporter gene construct containing the promoter region of the GSTA2 gene was generated according to methods described previously (14) . Briefly, the region containing Ϫ1651 to ϩ66 bp of the GSTA2 gene was amplified by PCR using pGTB-1.65 as a template. The PCR product was cloned into pGEM-T EasyVector (Promega) and subcloned into the pGL3 luciferase reporter plasmid. The deletion mutants of GSTA2 promoter-luciferase plasmid, pGL-⌬C/EBP and pGL-⌬ARE, in which the C/EBP binding site and ARE were deleted, respectively, were constructed by PCR-based methods. The specific PPRE mutant constructs of the GSTA2 promoter-luciferase reporter gene, pGL-mPPRE1, pGL-mPPRE2, and pGL-mPPRE3, were prepared by replacing the respective direct repeat (DR)1 site with 5Ј-CTCGAGAGAATTC-3Ј. The mutant plasmids were generated by the overlapping PCR technique and then ligated into the pGL3 plasmid. To increase RXR␣ expression, the coding region of RXR␣ derived from PECE-RXR␣ (HindIII and EcoRI digestion) was subcloned into pCDNA3.1 (Invitrogen, Carlsbad, CA; i.e., pCDNA-RXR␣). The DNA sequences of the constructs were verified by sequence analysis using an ABI7700 DNA cycle sequencer.
Cell Culture. H4IIE, a rat hepatocyte-derived cell line, and 3T3-L1, a murine preadipocyte cell line, were obtained from American Type Culture Collection (Rockville, MD). Cells were maintained in DMEM containing 10% FCS, 50 units/ml penicillin, and 50 g/ml streptomycin at 37°C in a humidified atmosphere with 5% CO 2 . 3T3-L1 preadipocytes were differentiated to adipocytes by incubating in the medium containing 10% FCS, 1 M dexamethasone, 1 g/ml insulin, and 0.5 mM 3-isobutyl-1-methylxanthine, as described previously (35) . Hepatic stellate cells and primary hepatocytes were isolated from male Sprague Dawley rats according to the method published previously with slight modifications (36) .
PPAR␥ Agonist and RA Treatment. PGJ 2 , troglitazone, pioglitazone, rosiglitazone, and RA, dissolved in DMSO, were added to H4IIE cells and incubated for the indicated time period for each experiment at 37°C. Cells were then washed twice with ice-cold PBS before sample preparation.
Preparation of a cDNA Probe for GSTA2. A cDNA probe for the GSTA2 gene was amplified by reverse transcription-PCR using selective primers (37) and cloned in the pGEM-T vector (Promega).
Preparation of Nuclear Extracts. Nuclear extracts were prepared according to methods published previously (14) . Briefly, H4IIE cells in dishes were washed twice with ice-cold PBS and then scraped from the dishes with PBS and transferred to microtubes. Cells were then centrifuged at 2,500 ϫ g for 3 min and allowed to swell after the addition of 100 l of hypotonic buffer containing 10 mM HEPES (pH 7.9), 10 mM KCl, 0.1 mM EDTA, 0.5% NP40, 1 mM DTT, and 0.5 mM phenylmethylsulfonylfluoride. The lysates were incubated for 10 min on ice and then centrifuged at 7,200 ϫ g for 5 min at 4°C. Pellets containing crude nuclei were resuspended in 50 l of extraction buffer containing 20 mM HEPES (pH 7.9), 400 mM NaCl, 1 mM EDTA, 10 mM DTT, and 1 mM phenylmethylsulfonyl fluoride and then incubated for 30 min on ice. The samples were then centrifuged at 15,800 ϫ g for 10 min to obtain supernatants containing nuclear fractions. Nuclear fractions were stored at Ϫ70°C until use.
Preparation of Cytosolic Fractions. H4IIE cells were washed twice with sterile PBS, scraped from their dishes, and sonicated to disrupt the membranes. Cytosolic fractions were prepared by differential centrifugation at 15,000 ϫ g for 15 min and stored at Ϫ70°C until use. Protein content was determined by the Bradford assay (Bio-Rad protein assay kit; Bio-Rad, Hercules, CA).
Northern Blot Analysis. Total RNA was isolated from H4IIE cells using the single-step method of thiocyanate-phenol-chloroform RNA extraction, and Northern blot analysis was carried out according to procedures described previously (37) . Briefly, total RNA was resolved by electrophoresis in a 1% agarose gel containing 2.2 M formaldehyde and transferred to nitrocellulose paper. The nitrocellulose paper was baked in a vacuum oven at 80°C for 2 h. The filter was then incubated with hybridization buffer containing 50% deionized formamide, 5 ϫ Denhardt's solution [0.1% Ficoll, 0.1% polyvinylpyrrolidine, and 0.1% BSA (Pentex Fraction V)], 0.1% SDS, 200 g/ml sonicated salmon sperm DNA, and 5 ϫ saline-sodium phosphate-EDTA [1 ϫ salinesodium phosphate-EDTA ϭ 0.15 M NaCl, 10 mM NaH 2 PO 4 , and 1 mM Na 2 EDTA (pH 7.4)] at 42°C for 1 h without probe. Hybridization was performed at 42°C for 18 h with a heat-denatured cDNA probe for GSTA2 that was random prime-labeled with [␣-32 P]dCTP. Filters were washed twice in 2 ϫ SSC (1 ϫ SSC ϭ 150 mM NaCl and 15 mM sodium citrate) and 0.1% SDS for 10 min at room temperature and twice in 0.1 ϫ SSC and 0.1% SDS for 10 min at room temperature. Filters were then washed once in a solution containing 0.1 ϫ SSC and 0.1% SDS for 1 h at 60°C. After quantitation of GSTA2 mRNA levels via scanning densitometry, the membranes were stripped and rehybridized with a 32 P-labeled cDNA probe for 18S rRNA to control for RNA loading onto the membranes. Four separate experiments were performed with different RNA samples.
Immunoblot Analysis. SDS-PAGE and immunoblot analysis were performed according to procedures published previously (37) . Briefly, proteins were separated by 7.5 or 12% gel electrophoresis and electrophoretically transferred to nitrocellulose paper. The replicate SDS-PAGE gels were stained with Coomassie Blue for verification of equal loading of proteins before immunoblotting. The nitrocellulose paper was incubated with an anti-GST␣ antibody (Detroit R&D, Detroit, MI), followed by incubation with a horseradish peroxidase-conjugated secondary antibody. Specificity of the antibodies to the GST subunit has been confirmed previously (8, 37) . Immunoreactive protein was visualized through incubation with an enhanced chemiluminescence detection kit (Amersham Biosciences, Buckinghamshire, United Kingdom; Ref. 8) . Equal loading of proteins was verified by actin immunoblotting with a goat antiactin antibody (Santa Cruz Biotechnology). Three or four separate experiments were performed with different cytosolic samples. Changes in the levels of GSTA2 protein in the cells treated with PPAR␥ agonist ϩ RA relative to that in untreated control were determined via scanning densitometry. Similarly, PPAR␥, Nrf2, and C/EBP␤ were immunochemically detected with their respective antibodies (Santa Cruz Biotechnology). At least three separate experiments were performed with different subcellular fractions (or lysates) to confirm changes in the protein levels.
Scanning Densitometry. Scanning densitometry of the Northern and immunoblots was performed with Image Scan & Analysis System (AlphaInnotech Corp., San Leandro, CA). The area of each lane was integrated using the software AlphaEase version 5.5, followed by background subtraction.
Gel Shift Assay. A double-stranded DNA probe containing the GSTA2 gene ARE end-labeled with [␥-32 P]ATP, and T 4 polynucleotide kinase was used for gel shift analysis. The sequence of the ARE-containing oligonucleotide was 5Ј-GATCATGGCATTGCACTAGGTGACAAAGCA-3Ј. Similarly, C/EBP gel shift analysis was carried out with the radiolabeled oligonucleotide, 5Ј-TGCAGATTGCGCAATCTGCA-3Ј, which contained the C/EBP consensus sequence. The consensus PPRE sequence was 5Ј-CCAAGGTCAAAGGT- Immunoreactive protein was visualized through incubation with horseradish peroxidase-conjugated secondary antibody and an enhanced chemiluminescence detection kit. Equal loading of proteins was verified by probing the replicate blots for actin. Changes in GSTA2 protein levels relative to control were assessed by scanning densitometry. B, Northern blot analyses of GSTA2 mRNA. Northern blot analysis was performed with total RNA fractions (30 g each) prepared from the cells incubated with 100-1000 nM PGJ 2 for 24 h (left) or in the cells treated with 300 nM PGJ 2 for 3-24 h (right). The equal loading of RNA in each lane was confirmed by rehybridization of the stripped membrane with a 32 P-labeled probe for 18S rRNA. Changes in the GSTA2 mRNA expression relative to control were assessed by scanning densitometry and normalized by RNA loading. C, immunoblot analyses of NF-E2-related factor (Nrf)2 or CAAT/enhancer binding protein (C/EBP)␤ and gel shift assays of Nrf2 or C/EBP␤ DNA binding. Nuclear fractions were prepared from H4IIE cells treated with 300 nM PGJ 2 for 1-12 h. Gel shift assays were conducted with nuclear extracts prepared from H4IIE cells exposed to PGJ 2 (300 nM) for 1-12 h and 5 ng of radiolabeled antioxidant response element (ARE) or C/EBP-binding oligonucleotide. Arrowheads, the DNA bound with proteins. Results were confirmed by three separate experiments, and a representative immunoblot is shown. Data represent the mean Ϯ SD with three separate experiments. Oneway ANOVA was used for comparisons of multiple group means followed by Newman-Keuls test (significant as compared with control, ‫,ء‬ P Ͻ 0.05; ‫,ءء‬ P Ͻ 0.01; control level ϭ 1).
TRANSACTIVATION OF THE PPAR-RESPONSIVE ENHANCER MODULE
Research. CATGT-3Ј. To study the binding of nuclear hormone receptors to the DNAbinding sites, double-stranded PPRE oligonucleotides derived from PPRE1, 5Ј-CCATCGGTGATGACCTTGT-3Ј; PPRE2, 5Ј-TTGGCAGGAAGGAT-CAGTA-3Ј; and PPRE3, 5Ј-AACAGGACAAAGATTAAGA-3Ј present in the promoter region of the GSTA2 gene were used as probes. The reaction mixture contained 4 l of 5 ϫ binding buffer [containing 50 mM Tris-Cl (pH 7.5), 20% glycerol, 5 mM MgCl 2 , 250 mM NaCl, 2.5 mM EDTA, 2.5 mM DTT, and 0.25 mg/ml poly dI-dC], 10 g of nuclear extract, and sterile water up to a total volume of 20 l. The reaction mixture was preincubated without probe at room temperature for 10 min. The probe (1 l, containing 10 6 cpm) was then added, and DNA-binding reactions were carried out for 30 min at room temperature. In some analyses, specificity of binding was determined by competition experiments, which were carried out by adding a 10-fold molar excess of an unlabeled ARE, C/EBP, or PPRE oligonucleotide to the reaction mixture before the labeled probe was added. SP-1 oligonucleotide (5Ј-ATTC-GATCGGGGCGGGGCGAGC-3Ј) was used as a negative control for competition experiments. In other analyses, known as immuno-inhibition assays, antibodies directed to Nrf2, C/EBP␣, C/EBP␤, PPAR␥, and RXR␣ (2 g each) were added to the reaction mixture 20 min after the labeled probe was added, and the reaction was then continued for 1 h at 25°C. Samples were separated on 4% polyacrylamide gels at 100 V. The gels were fixed with 40% methanol/10% acetic acid, dried, and subject to autoradiography.
Luciferase Reporter Gene Analysis. We used the dual-luciferase reporter assay system (Promega). Briefly, H4IIE cells (7 ϫ 10 5 cells/well) were replated in six-well plates overnight, serum starved for 12 h, and transiently transfected with each GSTA2 promoter-luciferase construct and pRL-SV plasmid (a plasmid that encodes for Renilla luciferase and is used to normalize transfection efficacy) in the presence of LipofectAMINE Plus Reagent (Life Technologies, Inc. Gaithersburg, MD) for 3 h. Transfected cells were incubated in DMEM containing 1% FCS (Life Technologies) for 3 h and exposed to PGJ2 ϩ RA (50 nM each) in medium containing 10% FCS for 18 h at 37°C. Firefly and Renilla luciferase activities in cell lysates were measured using a Luminoskan luminometer (Thermo Labsystems, Helsinki, Finland). The activity of firefly luciferase was measured by adding Luciferase Assay Reagent II (Promega) according to the manufacturer's instruction, and, after quenching the reaction, the Renilla luciferase reaction was initiated by adding Stop & Glo reagent (Promega). The relative luciferase activity was calculated by normalizing firefly luciferase activity to that of Renilla luciferase. Northern blot analysis was performed with total RNA fractions (30 g each) prepared from the cells incubated with 10 -300 nM RA for 24 h (left) or 300 nM RA for the indicated times (right). C, immunoblot analyses of NF-E2-related factor (Nrf)2 or CCAAT/enhancer binding protein (C/EBP)␤ and gel shift assays of Nrf2 or C/EBP␤ DNA binding. Nuclear fractions were prepared from H4IIE cells treated with 300 nM RA for 1-12 h. Gel shift assays were conducted as described in the legend to Fig. 2C . Immunoblot analyses of Nrf2 and C/EBP␤ in the nuclear fractions. Nrf2 and C/EBP␤ were immunoblotted in the nuclear fractions of the cells treated with 300 nM RA for 1-12 h. Results were confirmed by three separate experiments, and a representative immunoblot is shown. Data represent the mean Ϯ SD with four separate experiments. One-way ANOVA was used for comparisons of multiple group means followed by NewmanKeuls test ‫,ء(‬ P Ͻ 0.05, significant as compared with control; ‫,ءء‬ P Ͻ 0.01, control level ϭ 1).
Research. Statistical Analysis. Scanning densitometry was performed with Image Scan & Analysis System (Alpha-Innotech). One-way ANOVA procedures were used to assess significant differences among treatment groups. For each significant effect of treatment, the Newman-Keuls test was used for comparisons of multiple group means. The criterion for statistical significance was set at P Ͻ 0.05 or Ͻ0.01. All statistical tests were two sided.
RESULTS
GSTA2
Induction by PGJ 2 . The PPAR␥1 expression level was higher than that of PPAR␥2 in most tissue types (15) . To examine the role of PPAR␥ in GSTA2 expression, we first assessed the PPAR␥ levels in H4IIE hepatocytes and other representative cells. Immunoblot analysis revealed that mainly PPAR␥1 was expressed in H4IIE cells (Fig. 1, left panel) . PPAR␥1 was also expressed in the primary cultured hepatocytes or stellate cells isolated from the rat liver (Fig. 1,  middle panel) . It was reported that the PPAR␥ expression level was high in adipocytes (␥1 is expressed to a greater extent than ␥2) but not in the preadipocytes, 16 which was also confirmed by immunoblot analysis (Fig. 1, right panel) .
We then determined whether or not PGJ 2 , an activator of PPAR␥, induced GSTA2 in H4IIE cells. PGJ 2 , at concentrations of 300 or 1000 nM, increased the GSTA2 protein levels (Fig. 2A) . A time course study showed that PGJ 2 (300 nM) induced GSTA2 2-fold at 6 -24 h. The GSTA2 mRNA levels were also increased by PGJ 2 (Fig. 2B) . Apparently, PGJ 2 at relatively high concentrations weakly induced GSTA2.
To determine whether PGJ 2 increases the binding activity of Nrf2 to the ARE, the nuclear extract isolated from the H4IIE cells treated with 300 nM PGJ 2 was probed with the radiolabeled GSTA2 gene ARE. Subcellular fractionation and immunoblot analyses showed that PGJ 2 weakly increased the Nrf2 level in the nuclear fraction (Fig. 2C,  left panel) . Immunoblot assay of the nuclear fractions and gel shift analysis confirmed that PGJ 2 weakly enhanced the band intensity of Nrf2 ARE binding at 6 h, whereas that of C/EBP␤ was minimally affected by PGJ 2 (Fig. 2C, right panel) . Gel shift analysis of protein binding to the C/EBP-binding site was performed with the nuclear extracts using a radiolabeled C/EBP-binding oligonucleotide. PGJ 2 minimally changed C/EBP DNA binding, which varied during the 6 -12-h time period (Fig. 2C, right panel) . GSTA2 Induction by RA. Next, we determined whether RA could induce GSTA2. Treatment of the H4IIE cells with RA (10 -300 nM), a ligand of RXR, for 24 h increased the GSTA2 protein level in a concentration-dependent manner (Fig. 3A ). RA at concentrations of 100 or 300 nM induced GSTA2 2-3-fold with the maximum induction being observed at 300 nM. A time course study showed that RA gradually induced the GSTA2 protein level from 6 h with the maximum increase being noted at 24 h. Northern blot analyses confirmed that the level of GSTA2 mRNA increased after exposure of cells to 300 nM RA (Fig. 3B) . The GSTA2 mRNA level peaked at 12 h.
This study next examined whether or not RA activated Nrf2 and C/EBP␤. RA at 300 nM weakly induced the nuclear translocation of Nrf2 and C/EBP␤ (Fig. 3C) , as evidenced by the subcellular fractionation and immunoblot analysis. Gel shift analyses confirmed that RA at 300 nM weakly increased Nrf2 and C/EBP␤ binding to their respective consensus DNA oligonucleotides (Fig. 3C) . Immuno-inhibition experiments using specific antibodies directed against Nrf2, PPAR␥, and RXR␣ indicated that an increase in the Nrf2-ARE DNA-binding activity by RA was dependent on Nrf2 (Fig. 3C) . Correspondingly, the shift in the C/EBP DNA-binding complex was the result of C/EBP␤. Synergistic Induction of GSTA2 by PGJ 2 ؉ RA. PPAR␥ heterodimerizes with the RXR for activation, and the PPAR␥ Ϫ RXR heterodimers are widely expressed in the major organs, including the liver (15) . We determined whether PGJ 2 ϩ RA enhanced GSTA2 induction. GSTA2 was induced 2-fold by 100 nM RA but not 100 nM PGJ 2 . In contrast to the weak induction of GSTA2 by each agent alone, PGJ 2 ϩ RA (100 nM each) synergistically increased the GSTA2 protein level (Fig. 4A) . A preliminary study reported that PGJ 2 ϩ RA induced GSTA2 to the greatest extent at the 1:1 molar ratio. To determine the dose-response effect, the GSTA2 level was further assessed in the cells treated with PGJ 2 ϩ RA each at equal concentrations (i.e., 15, 50, or 100 nM) for 24 h (Fig. 4B) . The dose-response study revealed that GSTA2 induction was efficaciously increased by the PGJ 2 ϩ RA treatment (i.e., 3-4-fold increases at concentrations of 15 or 50 nM). Therefore, 50 nM PGJ 2 and RA each were selected for the subsequent experiments.
Synergistic Induction of GSTA2 by PPAR Agonists in Combination with RA. The studies were extended to verify the effects of the thiazolidinedione PPAR␥ agonists in combination with RA on the GSTA2 expression. Immunoblot analysis revealed that troglitazone (1-10 M) ϩ RA (50 nM) synergistically induced GSTA2, whereas either troglitazone (1-10 M) or RA alone only weakly increased the GSTA2 protein level (Fig. 5A ). Rosiglitazone at 1-10 M moderately induced GSTA2, which was also enhanced by a combination treatment with RA. Similarly, pioglitazone ϩ RA markedly increased the (Fig. 5A) . These results strongly support the conclusion that the activation of the PPAR␥ and RXR heterodimer leads to the induction of GSTA2.
Additional experiments were performed in the primary cultured hepatocytes to confirm that the activation of the PPAR␥ and RXR heterodimer induces GSTA2 in normal cells. Because the enhancement effect for GSTA2 expression by the PPAR␥ agonist was saturated at 10 M in H4IIE cells, 1 or 3 M the PPAR␥ agonist were chosen for this experiment. Troglitazone, rosiglitazone, or pioglitazone in combination with RA induced GSTA2 to a greater extent when compared with the PPAR␥ agonist alone at the concentrations examined (Fig. 5B) . Hence, the PPAR␥ and RXR heterodimer enhance GSTA2 expression in hepatocytes.
Activation of Nrf2 and C/EBP␤ by PGJ 2 ؉ RA. To confirm that PGJ 2 ϩ RA (50 nM each) activates Nrf2, immunoblot and gel shift assays were performed with the nuclear extracts of the cells treated with PGJ 2 ϩ RA. PGJ 2 ϩ RA increased the nuclear Nrf2 levels and its binding to a radiolabeled ARE consensus oligonucleotide at 6 -12 h. Binding of the protein to the ARE was competed with an excess amount of unlabeled ARE (Fig. 6A ). Immunoblot and gel shift analyses showed that the PGJ 2 ϩ RA treatment increased the C/EBP␤ levels in the nuclear fractions and C/EBP␤ binding to the C/EBP binding oligonucleotide compared with the control (Fig. 6B) . Competition experiments using excess quantities of unlabeled C/EBP or SP-1 oligonucleotides confirmed the specificity of C/EBP DNA binding. Supershift experiments indicated that the C/EBP-binding complex comprised of C/EBP␤ (Fig. 6B) . The band intensity of C/EBP DNA-binding complex was reduced by the anti-C/EBP␤ antibody but not the anti-PPAR␥ or -RXR␣ antibodies. Immunocytochemistry confirmed that Nrf2 and C/EBP␤, which were located mainly in the cytoplasm of control cells, had perinuclear and nuclear localization at 6 -12 h in the cells treated with PGJ 2 ϩ RA, suggesting that these transcription factors translocate into the nucleus (data not shown).
Increases in the Nrf2 and C/EBP␤ Expression Levels by PGJ 2 ؉ RA. Nrf2 and C/EBP␤ expression was next examined to determine whether it was affected by PGJ 2 ϩ RA. Immunoblot analysis revealed that PGJ 2 ϩ RA notably increased the Nrf2 levels in the total cell lysates at 6 -12 h (Fig. 7A) . C/EBP␤ expression also began to increase 3 h after the PGJ 2 ϩ RA treatment. C/EBP␤ was induced 2-3-fold after 6 -12 h in the cells exposed to PGJ 2 ϩ RA (Fig.  7B ). This indicates that PGJ 2 ϩ RA increased the Nrf2 and C/EBP␤ expression level, suggesting that induction of Nrf2 and C/EBP␤ might also contribute to Nrf2-and C/EBP␤-mediated GSTA2 induction. 
TRANSACTIVATION OF THE PPAR-RESPONSIVE ENHANCER MODULE
Research. 
Analysis of ARE and C/EBP-Response Element in the GSTA2
Promoter. The functional role of ARE and C/EBP-response element in transactivation of the GSTA2 gene by PGJ 2 ϩ RA was next examined. The reporter gene assays were performed using the H4IIE cells transfected with pGL-1651, which contained the luciferase structural gene downstream of the Ϫ1.65-kb GSTA2 promoter region (Fig. 8A) .
Exposure of the pGL-1651-transfected cells to PGJ 2 ϩ RA resulted in a 6-fold increase in the luciferase activity (Fig. 8B ). Either PGJ 2 or RA alone (50 nM each) was minimally active. To precisely define the role of the ARE sequence for the induction of GSTA2 by PGJ 2 ϩ RA, this study prepared pGL-⌬ARE, which is a chimeric gene construct with the ARE deleted (Fig. 8A) . The relative luciferase-inducible activity by PGJ 2 ϩ RA was markedly decreased in the H4IIE cells transfected with pGL-⌬ARE, compared with that in the cells transfected with pGL-1651 (Fig. 8B) . C/EBP␤ was next examined to determine whether it plays a role in GSTA2 induction by PGJ 2 ϩ RA. The luciferase inducibility was completely abolished in the cells transfected with pGL-⌬C/EBP (Fig. 8B) , which is a chimeric gene construct where the C/EBP response element was deleted (Fig. 8A) . To further confirm the functional role of C/EBP␤ in GSTA2 transcription, the constitutively active dominant-negative mutant of C/EBP (AC/EBP) was expressed in combination with the pGL-1651 luciferase reporter in H4IIE cells. The expression of AC/EBP substantially inhibited the ability of PGJ 2 ϩ RA to stimulate reporter gene expression from the pGL-1651 plasmid (Fig. 8B, inset) . The ability of PGJ 2 ϩ RA to stimulate reporter gene expression from pGL-1651 was not inhibited by transfecting the cells with pCMV500, a control plasmid. These results provide evidence that the ARE and C/EBP-response elements are both necessary for GSTA2 induction by PGJ 2 ϩ RA.
Binding of the PPAR␥ and RXR Heterodimer to the PPREs. Studies have shown that PPAR␥ heterodimerizes with RXR (probably RXR␣), which is activated by RA (38, 39) . Searching the GSTA2 Fig. 6 . Activation of NF-E2-related factor (Nrf)2 and CCAAT/enhancer binding protein (C/ EBP)␤ by prostaglandin J 2 (PGJ 2 ) ϩ 9-cis-retinoic acid (RA). A, immunoblot analysis of nuclear Nrf2 and gel shift analysis. Nrf2 was immunoblotted in the nuclear extracts prepared from H4IIE cells incubated with PGJ 2 ϩ RA (50 nM each) for 1-12 h. Gel shift analysis was performed with the nuclear fractions. Arrowheads, the antioxidant response element (ARE) binding complex. For competition assays, 10-fold molar excess of unlabelled ARE oligonucleotide or SP-1 oligonucleotide was added to the reaction mixture that included radiolabeled oligonucleotide (5 ng) and nuclear extracts prepared from H4IIE cells treated with PGJ 2 ϩ RA for 6 h. B, immunoblot analysis of C/EBP␤ and gel shift analysis of C/EBP␤ binding to the C/EBPbinding site. Nuclear extracts were prepared from H4IIE cells incubated with PGJ 2 ϩ RA (50 nM each) for 1-12 h. Arrowheads, the C/EBP␤ bound with DNA. Immunocompetition or unlabelled excess oligonucleotide assays of C/EBP binding to the C/EBP-binding site were performed with the nuclear extracts prepared from the cells treated with PGJ 2 ϩ RA (50 nM each) for 6 h. Results were confirmed by three separate experiments. Data represent the mean Ϯ SD with three separate experiments ‫,ء(‬ P Ͻ 0.05, significant as compared with control; ‫,ءء‬ P Ͻ 0.01, the band intensity in control cells ϭ 1). 
TRANSACTIVATION OF THE PPAR-RESPONSIVE ENHANCER MODULE
Research. promoter region with the PPRE consensus sequence, AGGTCANAG-GTCA, resulted in three putative response elements (i.e., PPRE1, PPRE2, and PPRE3), to which the activating PPAR␥ Ϫ RXR heterodimer might bind. The putative PPRE1 sequence present at Ϫ792 bp from the transcription start site contained a reverse DR1 site, whereas the other DR1 sites named PPRE2 and PPRE3 were present at Ϫ746 and Ϫ549 bp, respectively (Fig. 9A) .
As part of the efforts to examine how PGJ 2 ϩ RA enhances the GSTA2 gene induction, the activities of protein binding to the PPREs were determined. Gel shift analyses revealed that PGJ 2 ϩ RA increased the band intensities of protein binding to either the PPRE1 or PPRE2 oligonucleotide at 3-12 h (Fig. 9, B and C) . Similarly, PGJ2 ϩ RA treatment resulted in increases in protein binding to the PPRE3 at 3-6 h (Fig. 9D) . The protein-PPRE3-binding complex was immunodepleted with either an anti-PPAR␥ antibody or anti-RXR␣ antibody (Fig. 9E) . Competition experiments using excess amounts of unlabeled SP-1 or the PPRE3 oligonucleotide confirmed the specificity of protein DNA binding (Fig. 9E) . The specificity of PPAR␥ Ϫ RXR heterodimer binding to the other PPREs was also confirmed by immunodepletion and competition analyses with the unlabeled oligonucleotides (data not shown).
Functional Analysis of the PPREs in the GSTA2 Promoter. When the PPRE1 sequence located between the nucleotides Ϫ792 and Ϫ781 bp in pGL-1651 was mutated (Fig. 10A; i.e., pGL-mPPRE1), the inducible luciferase activity by PGJ 2 ϩ RA was completely reduced to that of the control (Fig. 10B) . For comparison, this study determined the effect of 3-methylcholanthrene, an AhR-xenobioticresponse element-mediating GSTA2 inducer, on the expression of pGL-mPPRE1 promoter reporter gene. Exposure of the H4IIE cells transfected with pGL-mPPRE1 to 3-methylcholanthrene increased the luciferase activity 8-fold compared with the untreated control (Fig.  10B) . The increase in luciferase activity was comparable with that in pGL-1651-transfected cells treated with 3-methylcholanthrene. These results indicated that the PPRE1 in the GSTA2 gene is selectively activated by PGJ 2 ϩ RA. The role of the PPRE2 or PPRE3 site in responsiveness was also examined using mutation analyses (Fig.  10A) . Mutation of each of the PPRE sites almost completely abolished the inducible expression of the pGL-1651 luciferase chimeric gene by PGJ 2 ϩ RA (Fig. 10C) . Either pGL-mPPRE2 or pGL-mPPRE3 also responded to 3-methylcholanthrene. These results demonstrate that PGJ 2 ϩ RA directly activates the PPRE enhancer activities in the GSTA2 gene and that the multiple PPRE-binding sites are essential for the full ligand responsiveness.
Effect of PPAR␥1 ؊ RXR␣ Overexpression on the GSTA2 Transactivation. This study examined the effects of PPAR␥1 and RXR␣ overexpression with or without ligands on the Nrf2, C/EBP␤, and GSTA2 gene expression. The H4IIE cells were transfected with the plasmids encoding PPAR␥1 and RXR␣, which were then exposed to PGJ 2 ϩ RA. Either PPAR␥1 or RXR␣ alone elicited a modest increase in the Nrf2 expression level. The concomitant expression of PPAR␥1 and RXR␣ to the larger extent enhanced the level of Nrf2 level in the total cell lysates (Fig. 11A, top panel) . Furthermore, PGJ 2 ϩ RA potentiated Nrf2 induction in the cells transfected with the PPAR␥1 and RXR␣ plasmids. Similarly, PPAR␥1 and RXR␣ overexpression caused an increase in the C/EBP␤ level in the total cell lysates. C/EBP␤ was further induced by PGJ 2 ϩ RA in the cells transfected with the plasmids (Fig. 11A, top panel) .
Additional experiments were performed using PPAR␥ selective agonists with or without RA to confirm that the ligand activation of PPAR␥ and RXR led to Nrf2 or C/EBP␤. RA (50 nM), pioglitazone, or rosiglitazone alone (3 M) failed to induce Nrf2 in the cell lysates. As expected, an increased Nrf2 expression level was noted in the cells treated with pioglitazone ϩ RA or rosiglitazone ϩ RA (Fig. 11A,  bottom panel) . However, troglitazone (3 M) with or without RA induced Nrf2, which suggested that troglitazone might elicit oxidative stress. Pioglitazone, rosiglitazone, or troglitazone in conjunction with RA induced C/EBP␤ to the greater extent, compared with their respective treatment alone (Fig. 11A, bottom panel) .
The extents of protein binding to the PPRE-binding sites in the GSTA2 gene were next determined. PPAR␥1 and RXR␣ overexpression in the H4IIE cells resulted in an increase in the band intensity of protein binding to PPRE3, which was enhanced by the PGJ2 ϩ RA treatment (Fig. 11B) . The addition of either the anti-PPAR␥ or -RXR␣ antibodies decreased the intensity of the shifted band, indicating that the binding proteins include PPAR␥ and RXR␣.
To examine the effect of the PPAR␥ and RXR heterodimer on transactivation of the GSTA2 gene, functional reporter gene analysis was performed on the cells transfected with pGL-1651. The functional role of the PPAR␥ and RXR heterodimer in responsiveness was verified by an increase in the luciferase inducibility (Fig. 11C) . The luciferase activity in the cells transfected with the plasmids encoding promoter-luciferase gene by prostaglandin J 2 (PGJ 2 ) ϩ 9-cis-retinoic acid (RA). A, the deletion mutants of GSTA2 luciferase chimeric construct. B, the effects of deletion mutation of ARE or C/EBP-response element on the induction of luciferase activity by PGJ 2 ϩ RA. Dual luciferase reporter assays were performed on the lysates of H4IIE cells that had been cotransfected with the GSTA2-luciferase gene construct pGL-1651 (firefly luciferase) and pRL-SV (Renilla luciferase) at a ratio of 200:1 and subsequently exposed to PGJ 2 , RA, or PGJ 2 ϩ RA (50 nM each). Activation of the reporter gene was calculated as a change in the ratio of firefly luciferase activity to Renilla luciferase activity. PGJ 2 ϩ RA significantly induced luciferase activity in H4IIE cells transiently transfected with GSTA2 chimeric gene construct pGL-1651, which contains both the C/EBP response element and ARE of the GSTA2 promoter. Deletion mutation of the C/EBP response element or ARE completely abolished the luciferase induciblity by PGJ 2 ϩ RA. Inset, the inhibition of PGJ 2 ϩ RA-inducible pGL-1651 reporter gene activation by the dominantnegative mutant of C/EBP (AC/EBP). H4IIE cells were cotransfected with pGL-1651/ pRL-SV (200:1) in combination with pCMV500 or pCMV-AC/EBP at a ratio of 1:1, and luciferase activity was measured at 18 h after transfection. The experimental value for luciferase activity was expressed as a relative luciferase unit of cell lysate and represented the mean Ϯ SD with four separate experiments (significant as compared with control, PGJ 2 , or RA alone, ‫,ءء‬ P Ͻ 0.01; significant as compared with the respective treatment in cells transfected with pGL-1651, ## , P Ͻ 0.01; significant as compared with pCMV500-transfected cells treated with PGJ 2 ϩ RA, † † , P Ͻ 0.01).
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on October 29, 2017. © 2004 American Association for Cancer cancerres.aacrjournals.org Downloaded from PPAR␥1 and RXR␣ was comparable with that of the control cells treated with PGJ 2 ϩ RA. The luciferase reporter gene expression level was further increased after exposing the cells transfected with the PPAR␥1 and RXR␣ plasmids to PGJ 2 ϩ RA (Fig. 11C ). The results demonstrate that the PPAR␥ and RXR heterodimer, which interacts with the multiple PPRE-binding sites, makes crucial contribution to the inducible expression of the GSTA2 gene.
DISCUSSION
The nuclear receptors are ligand-dependent transcription factors that regulate the gene networks involved in controlling cell growth, morphogenesis, differentiation, and homeostasis. Activation of the nuclear receptor homodimers and heterodimers in response to the ligands requires binding of the nuclear receptors to the response elements that contain two core recognition sequences (i.e., half-sites). PPARs, including PPAR␣, PPAR␤/␦, and PPAR␥, constitute a subfamily of the nuclear receptor superfamily activated by a variety of natural and chemical ligands. The PPAR genes are involved in regulating the lipid metabolism (40 -42) . The RXRs, as members of the nuclear receptor superfamily, are the common heterodimeric partner for many receptors, including PPAR. The RXRs are modular proteins with a highly conserved central DNA-binding domain and less conserved ligand-binding domain (43) . RXR serves as a permissive partner of PPARs. Although the effects of the PPAR subfamily on the lipid metabolism have been extensively studied, a proper examination of the role of PPARs in the transcriptional regulation of the Phase II detoxification genes has not been reported.
There are reports showing that PPAR␥1 is expressed in the adipocytes and hepatic stellate cells with PPAR␥2 being less frequently expressed (15, 16, 44 ). In the current study, it was shown that PPAR␥1 was sufficiently expressed in the H4IIE and primarycultured hepatocytes. It was revealed that either PPAR␥ or RXR agonist results in the induction of GSTA2 with increases in the mRNA and that treatment of the cells with the PPAR␥ and RXR agonists synergistically induces GSTA2. This was also observed in the cells treated with nanomolar concentrations of PGJ 2 and RA. PGJ 2 at nanomolar concentrations served as a ligand of PPAR␥. Enhanced GSTA2 induction by PGJ 2 ϩ RA, compared with that by each agent alone, demonstrates that PPAR␥ and RXR heterodimer activation may contribute to the enzyme induction. This was further supported by the observation that the PPAR␥ ligand, troglitazone, rosiglitazone, or pioglitazone, in combination with RA, induced GSTA2 to a much greater extent. A discrepancy in the effective concentration range between PGJ 2 (50 nM) and thiazolidinedione PPAR␥ agonist (1-10 M) for GSTA2 induction may have resulted from the difference in their equilibrium dissociation rate constants for PPAR␥. This is re- flected by the high-affinity displacement of the binding of a radiolabeled thiazolidinedione to recombinant PPAR␥ by PGJ 2 in a cell lysate system (45) . Therefore, it is likely that PPAR␥ activation contributes to GSTA2 induction. Despite the weak induction of GSTA2 by RA alone, RA potentiated the enzyme induction by PPAR␥ agonist. These results suggested that ligand activation of RXR␣ is needed for the full responsiveness in GSTA2 induction by the PPAR␥ activator.
The expression of the Phase II detoxifying enzyme is transcriptionally activated partly through the activation of Nrf2 via the Nrf2 binding to the ARE in the promoter regions of the target genes (2, 3). Nrf2 activation plays an important role in the induction of many Phase II detoxifying enzymes, and the lack of Nrf2/ARE activation increases the sensitivity to xenobiotics, including carcinogens (46 -48) . We reported previously that tert-butylhydroquinone, a representative prooxidant, activated Nrf2 for GSTA2 induction (9, 49 ). In the current study, it was shown that either PGJ 2 or RA alone at relatively high concentrations elicited Nrf2 translocation and its DNA binding in the H4IIE cells, whereas PGJ 2 or RA at nanomolar concentrations required each other for Nrf2 activation. In addition, PGJ 2 ϩ RA induced Nrf2. We found that the promoter region of the Nrf2 gene contains the putative PPRE site (GenBank no. U70474, mouse Nrf2 promoter), which potentially interacts with the activating PPAR␥ Ϫ RXR heterodimer. Therefore, both the presence of the binding sites for PPAR␥ Ϫ RXR in the promoter region of the Nrf2 gene and the efficacious GSTA2 induction by nanomolar concentrations of PGJ 2 and RA indicate that the PPAR␥ and RXR heterodimer activates the Nrf2 gene induction, which contributes to the GSTA2 induction.
Previous studies showed that cancer chemopreventive agents, including oltipraz and flavonoids, activate C/EBP␤ and stimulate C/EBP␤ binding to the C/EBP-response element in the GSTA2 gene (13, 14) . The essential role of the C/EBP-binding site in GSTA2 induction was further supported by an experiment using a dominantnegative mutant C/EBP (AC/EBP) in the reporter gene assay, which holds significant implication for the finding of C/EBP␤ as an important transcription factor for GSTA2 induction. The NH 2 -terminal transactivation domains of C/EBP␤ interact with CBP/p300 coactivator after binding to the C/EBP site, which is essential for C/EBP␤-mediated gene transactivation (50) . In the present study, it was observed that a combined treatment of the cells with either PGJ 2 and RA induced the nuclear translocation of C/EBP␤ and activating C/EBP␤ binding to the C/EBP response element. In addition, PGJ2 ϩ RA increased the C/EBP␤ expression level. The C/EBP␤ gene contains PPRE sites (GenBank no. AY056052). It is likely that C/EBP␤ induction via PPAR␥ and RXR␣ heterodimer binding to the PPREs in the promoter region of the C/EBP␤ gene is also responsible for inducing GSTA2.
This study provides evidence that both the ARE and C/EBPbinding site have essential roles in the transactivation of the GSTA2 gene by PPAR␥ and RXR ligands, as evidenced by the binding site-deleted promoter-luciferase assay. The complete blockage of the PPAR␥ and RXR␣-mediated induction of the GSTA2 gene as a result of a deletion mutation of either the ARE or C/EBP-binding site confirms the previous observation that the binding of Nrf2 and C/EBP␤ to their response elements is simultaneously necessary for the full gene transactivation (Fig. 12A ; Refs. 13 and 14) . It is inferred that the formation of the transcriptional protein complexes on the two essential binding sites is required for the full responsiveness to chemical inducers.
The retinoic acid receptor and RXR␣ heterodimer activate tran- Fig. 10 . The role of putative peroxisome proliferator-activated receptor-response elements (PPREs) in the transcription of glutathione S-transferase A2 promoter-luciferase gene by prostaglandin J 2 (PGJ 2 ) ϩ 9-cis-retinoic acid (RA). A, the PPRE mutant constructs of pGL-1651. B, the effects of PPRE mutation on the induction of luciferase activity by PGJ 2 ϩ RA. Dual luciferase reporter assays were performed in H4IIE cells transiently transfected with pGL-mPPRE1, in which the PPRE1 was mutated. C, inducible glutathione S-transferase A2-luciferase activities in the cells transfected with the PPRE mutant plasmids. The relative luciferase inducibility by PGJ 2 ϩ RA was obtained from the ratio of activity in pGL-mPPRE2-or pGLmPPRE3-transfected cells to that in pGL-1651-transfected cells. The experimental value for luciferase activity represented the mean Ϯ SD with four separate experiments (significant as compared with pGL-1651-transfected cells exposed to PGJ 2 ϩ RA, ‫,ءء‬ P Ͻ 0.01). scription in response to the retinoic acid receptor-specific ligands on the DR5 elements but constitutively repress transcription on the DR1 elements (51) . The PPAR␥ and PPAR␥ Ϫ RXR␣ heterodimers have different DNA-binding specificities with preferential binding of the latter to DR1. The present finding of PPAR␥ and RXR heterodimer binding to the DR1 and functional role of the heterodimer in transactivating the GSTA2 gene excludes the possibility that the retinoic acid receptor-RXR heterodimer is involved in the transactivation of the GSTA2 gene. This is in parallel with the suppression of GSTP1 expression by RA in the presence of retinoic acid receptor as a result of the decreased transcription from its promoter (52) . PGJ 2 alone (at nanomolar concentrations) is a weak inducer of GSTA2, because the PPAR␥ Ϫ RXR heterodimer requires the binding of an RXR ligand. The role of the PPAR␥ and RXR heterodimer in GSTA2 gene transactivation was confirmed by the comparable induction of GSTA2 by the thiazolidinedione PPAR␥ activator and RA. SRC-1 is a coactivator of PPAR␥ (53) . Binding of the ligand-activated PPAR␥ Ϫ RXR␣ heterodimer to its DNA-binding sites stimulates the interaction between PPAR␥ Ϫ RXR␣ and p160/SRC-1 (53) .
The observation that the ligand-activated PPAR␥ Ϫ RXR heterodimer binds the regulatory PPREs independent of their activation and the induction of Nrf2 and C/EBP␤ led us to examine the functional role of each of these PPRE-binding sites containing the DRs related to the hexamer AGGTCA in the GSTA2 gene. Specific mutations of these nuclear binding sites in the GSTA2 promoter, which are present as a three PPRE cluster, resulted in the complete loss of its responsiveness to PGJ 2 ϩ RA. We showed that all of the putative PPRE sites comprising DR1 are functionally active. Therefore, the binding of the activating PPAR␥ Ϫ RXR heterodimer to all of the PPRE sites is crucial for the inducible gene activation (Fig. 12B) . Blockage of the ligand-dependent transcriptional response as a result of a mutation of the respective binding site suggests that the multiple putative PPREs function as a module in which the nuclear binding sites in close proximity to each other are essential for full ligand responsiveness. Therefore, it is highly likely that the PPAR-binding site cluster is the functionally active PPREM in the GSTA2 gene. Consistent with this, the essential role of the PPAR␥ Ϫ RXR heterodimer and PPRE-binding elements in activation, the GSTA2 gene was further supported by the reporter gene induction experiments. It was observed that transcription of the GSTA2 gene was further enhanced by exposing the cells transfected with the plasmids encoding PPAR␥ and RXR␣ to their corresponding ligands. This study on the regulation of GSTA2 gene expression by the PPAR␥ Ϫ RXR heterodimer at the promoter containing DR1 elements brings additional insights into the transcriptional control mechanism of the Phase II enzyme involved in carcinogen detoxification.
Nrf2 and C/EBP␤ play essential roles in gene transactivation. Now, we report that the activating PPAR␥ and RXR heterodimer functionally regulates PPREM activity via the proximal promoter of the GSTA2 gene and confers full responsiveness to the PPAR␥ and RXR Fig. 11 . The functional role of peroxisome proliferatoractivated receptor (PPAR)␥1 and retinoid X receptor (RXR)␣ overexpression in gene transactivation. A, the effects of PPAR␥1 and RXR␣ overexpression or ligand activation of PPAR␥ and RXR on the expression of NF-E2-related factor (Nrf)2 and CCAAT/enhancer binding protein (C/EBP)␤. The levels of Nrf2 and C/EBP␤ were immunochemically measured in the cells transfected with the plasmids encoding PPAR␥1 and/or RXR␣. Cells were transfected with an empty vector or the PPAR␥1 and/or RXR␣ plasmids (500 ng each) in the presence of LipofectAMINE for 3 h, exposed to the medium containing 1% FCS for 12 h, and then treated with prostaglandin J 2 (PGJ 2 ) ϩ 9-cis-retinoic acid (RA; 50 nM each) for an additional 12-h time period. pCMX and pCDNA3.1 were included as empty vectors to transfect cells with the same amount of plasmids (a total of 1 g of DNA). In another set of experiments, H4IIE cells were treated with PPAR␥-selective agonists (3 M) with or without RA (50 nM) for 12 h. The levels of Nrf2 and C/EBP␤ were immunochemically determined in the cell lysates. Each lane contained 15 g of proteins. Results were confirmed by repeated experiments. B, gel shift analysis of PPAR␥ and RXR␣ binding to the putative peroxisome proliferator-activated receptor-response element (PPRE). Nuclear extracts were prepared from the H4IIE cells transfected with the PPAR␥1 and/or RXR␣ plasmids with or without PGJ 2 ϩ RA (50 nM each). Fifteen g of nuclear extracts were incubated for 30 min with 5 ng of radiolabeled PPRE oligonucleotide and separated on 4% polyacrylamide gel. Arrowhead, the protein PPRE-binding complex. The nuclear extract was immunodepleted with an anti-PPAR␥ antibody or -RXR␣ antibody (2 g). Excess of unlabelled PPRE oligonucleotide was added to the reaction mixture for a competition assay. Results were confirmed by repeated experiments. C, activation of the pGL-1651 glutathione S-transferase A2 gene by PPAR␥1 and RXR␣ overexpression. H4IIE cells were transfected with the pGL-1651 luciferase reporter plasmid (1 g) and plasmid of Renilla luciferase (5 ng) after transfection with the PPAR␥1 and/or RXR␣ plasmid (500 ng each) for 3 h and incubated for 12 h in the medium with 1% FCS. The cells were treated with PGJ 2 ϩ RA (50 nM each) for 18 h, and the cell extracts were assayed for firefly and Renilla luciferase activities. The fold inductions of the normalized luciferase activity were compared with that in control cells transfected with the pGL-1651 (1 g) and empty plasmids (500 ng each of pCMX and pCDNA3.1). Data represented the mean Ϯ SE with three separate experiments (significant as compared with the cells transfected with empty plasmids, ‫,ءء‬ P Ͻ 0.01; significant as compared with the cells transfected the PPAR␥1 and RXR␣ plasmids, ## , P Ͻ 0.01).
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on October 29, 2017. © 2004 American Association for Cancer cancerres.aacrjournals.org Downloaded from ligands in association with the activating Nrf2 and C/EBP␤ (Fig.  12B) . Both Nrf2 and C/EBP␤ are up-regulated in a PPAR␥-and RXR-dependent manner. However, the induction of Nrf2 and C/EBP␤ resulted in little or no activation of the GSTA2 promoter in the cells transfected with a GSTA2 promoter-reporter construct containing the sequentially mutated PPAR response elements. These results suggest that the PPAR response module, which was activated by the ligandbound PPAR␥ and RXR heterodimer, may be essential for the formation of the transactivation complexes comprising Nrf2 and C/EBP␤. The essential role of PPAR␥ binding to its target DNA element for enhancesome-mediated gene activation is further supported by the findings that activating transcription factors, such as PPAR␥, Nrf2, and C/EBP␤, form complexes with coregulators (e.g., CBP/p300; Ref. 53) and that PPAR␥ binds to Nrf2 (54) . An additional study revealed that PPAR␥ and RXR␣ agonists induced other forms of GST, including GSTA3 in H4IIE cells (data not shown). A search of the GenBank database showed that the putative PPRE containing DR1 element is located in the promoter region of the rat GSTA3 gene (GenBank no. AF067442). Therefore, the PPAR␥ Ϫ RXR heterodimer may serve as a common transcriptional factor complex for inducing the GSTs in the liver.
In conclusion: (a) PPAR␥ agonist ϩ RA both activate and induce Nrf2 and C/EBP␤; (b) activating Nrf2 and C/EBP␤ binding to the antioxidant-and C/EBP-response elements stimulates the expression of the GSTA2 gene in response to the PPAR␥ and RXR agonists; (c) the promoter region of the GSTA2 gene contains the multiple PPRE cluster, which interacts with the PPAR␥ Ϫ RXR heterodimer; and (d) the PPRE-binding sites present in the GSTA2 promoter might function as a PPREM for transactivation the GSTA2 gene. The fact that PPAR␥ Ϫ RXR activation plays a key role in GST induction via direct gene transactivation, as well as the coordinate induction of the activating Nrf2 and C/EBP␤, provides implication that dietary components, including fatty acids and retinoids, strongly affect GST regulation, whose transcription confers cancer chemoprevention, as well as the detoxification of xenobiotics and toxicants.
